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Background: Hypertension has been cited as the most common attributable risk factor for death worldwide, and
in Canada more than one of every five adults had this diagnosis in 2007. In addition to different lifestyle
modifications, such as diet and exercise, there exist many pharmaco-therapies from different drug classes which can
be used to lower blood pressure, thereby reducing the risk of serious clinical outcomes. In moderate and severe
cases, more than one agent may be used. The optimal mono- and combination therapies for mild hypertension
and moderate/severe hypertension are unclear, and clinical guidelines provide different recommendations for first
line therapy. The objective of this review is to explore the relative benefits and safety of different
pharmacotherapies for management of non-diabetic patients with hypertension, whether of a mild or moderate to
severe nature.
Methods/Design: Searches involving MEDLINE and the Cochrane Database of Systematic Reviews will be used to
identify related systematic reviews and relevant randomized trials. The outcomes of interest include myocardial
infarction, stroke, incident diabetes, heart failure, overall and cardiovascular related death, and important side effects
(cancers, depression, syncopal episodes/falls and sexual dysfunction). Randomized controlled trials will be sought.
Two reviewers will independently screen relevant reviews, titles and abstracts resulting from the literature search,
and also potentially relevant full-text articles in duplicate. Data will be abstracted and quality will be appraised by
two team members independently. Conflicts at all levels of screening and abstraction will be resolved through
team discussion. Random effect pairwise meta-analyses and network meta-analyses will be conducted where deemed
appropriate. Analyses will be geared toward studying treatment of mild hypertension and moderate/severe
hypertension separately.
Discussion: Our systematic review results will assess the extent of currently available evidence for single agent and
multi-agent pharmacotherapies in patients with mild, moderate and severe hypertension, and will provide a rigorous
and updated synthesis of a range of important clinical outcomes for clinicians, decision makers and patients.
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Blood pressure (BP) is a measure of the pressure that
blood places against the walls of blood vessels during
circulation [1], measured in terms of systolic BP (SBP;
normal values <130 mmHg) and diastolic BP (DBP;
normal values <85 mmHg). When SBP rises above 140
mmHg or DBP rises above 90 mmHg, the patient is
considered to have hypertension [1,2]. Hypertension is a
chronic condition which places increased stress on the
heart and blood vessels, and represents a critical risk
factor for clinically significant events including myocardial
infarction (MI), heart failure, stroke and death. Hyperten-
sion is the most common attributable risk factor for death
worldwide, and an independent predictor of stroke
mortality and ischemic heart disease mortality [3,4]. In
2007, more than one of every five adult Canadians
suffered from high BP [5-7].
Reduction of elevated BP is associated with a reduction
in the risk of clinically significant events. Evidence
supports a direct correlation between the magnitude
of BP reduction and the rate of major events, and thus
treatment is geared toward lowering BP to below 140
SBP/90 DSP in most patients [8,9]. In addition to lifestyle
changes, there exists a number of classes of antihyperten-
sive pharmacotherapies which can be used to manage BP.
Classes of agents include diuretics, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers,
calcium channel blockers, beta blockers and alpha blockers,
among others. Guidance from the Canadian Hypertension
Education Program (CHEP) [2] suggests initial therapy
should consist of monotherapy using any one among
thiazide diuretics, beta-blockers, ACE inhibitors, long-
acting calcium channel blockers or angiotensin receptor
blockers (ARB). It is further recommended that use of a
second agent should be considered if target BP is not
achieved with monotherapy, with a choice made among
the agents considered for first line monotherapy. More
than 66% of patients with hypertension cannot have their
BP adequately lowered using monotherapy, and so the
addition of a second agent (and third) may be required [10].
A first question in clinical practice is about choice of
therapy, and which treatment should be given to a patient
first to minimize risk of undesirable outcomes. Pharmaco-
therapies are associated with different mechanisms of
action, harm profiles and costs. The optimal choice of a
first line agent remains unclear, as some works suggest
that thiazide diuretics are best [11,12], while others suggest
calcium channel blockers should be considered as first
line therapy in patients over 55 years of age or of Caribbean
or African descent [13]. In Canada, all but alpha
blockers are considered reasonable first line therapies,
with patients’ demographics and comorbidities playing a
role in selection [2]. There also has been relatively little
study to assess the relative effectiveness of combinationtherapies, which may be used in moderate to severe cases
of hypertension.
To address these research gaps and discrepancies in
guidance, the planned study will be a systematic review
incorporating network meta-analyses to explore the relative
effectiveness and safety of different monotherapies and
combination therapies for hypertension. The planned
review will include thiazide diuretics, ACE inhibitors, ARBs,
calcium channel blockers, beta blockers, alpha blockers,
placebo, no treatment and a combination antihypertensive
therapy. Separate analyses to address benefits in different
degrees of hypertension will be pursued.
Methods/Design
Selection of studies
The research question for this systematic review was speci-
fied according to the Population-Intervention-Comparator-
Outcome-Study Design framework. The following criteria
related to the study population, interventions and compar-
ators, clinical outcomes and study designs of interest will
be sought.
Population
Non-diabetic patients with hypertension are the target
population of interest. No restrictions will be used re-
garding gender. Studies in adult patients will be retained,
and subgroup analyses based on age (for example, age >60
years, age >75 years) will be explored. Studies of both first
line therapy (that is, mainly monotherapies) and second
line therapy (that is, mainly combination therapies) will be
included. Studies related to hypertension during pregnancy,
hypertensive emergencies and hypertension treatment
in acute stroke will be excluded. Studies conducted in
the following sub-populations will be eligible if all patients
in the study were required to have hypertension upon
entry, and if the benefits of BP lowering on outcomes were
examined in the study: patients with micro- and macro-
albuminuria; patients with metabolic disease; patients
with myocardial ischemia; patients with coronary artery
disease/atherosclerosis.
Interventions/Comparators
We will seek studies evaluating the following classes in
monotherapy and combination therapy regimens: calcium
channel blockers, beta blockers, angiotensin receptor
blockers, alpha blockers, thiazide diuretics, potassium
sparing diuretics and ACE inhibitors. Fixed doses for each
agent will not be sought as an inclusion criterion, as it is
anticipated that the majority of trials will have variable
doses titrated for each patient.
Outcomes
Studies that report one or more of the following clinical
outcomes will be included: MI, stroke, incident diabetes,
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treatment; and important adverse events which may
impact quality of life (for example, sexual dysfunction,
depression, syncopal episodes/falls, cancers). Where
outcome definitions vary across studies, appropriate sensi-
tivity analyses will be undertaken.
Study design
Randomized controlled trials of a minimum, one-year
duration will be included in this review. Only English
language studies will be retained, as past research sug-
gests that limiting included studies to the English lan-
guage does not greatly affect summary estimates from
meta-analyses [14,15].
Literature search strategy
Based on awareness of a large number of existing reviews
and network meta-analyses that can be leveraged, an
unlimited primary search for RCTs will not be performed.
In its place, we will use a staged approach to study identi-
fication, beginning with the identification of relevant trials
included in Cochrane systematic reviews searched for in
the Cochrane Database of Systematic Reviews (publication
years 2005 and onward) and existing network meta-analyses
of which we are aware [16-21]. Medline (OVID interface)
will next be searched to identify other relevant reviews,
and we will systematically compare studies from relevant
articles in reverse chronologic order until yield from this
approach becomes low. The Medline search is presented
in a supplemental Appendix, and was designed by a senior
information specialist in consultation with the review
team and peer reviewed using PRESS (Peer Review of
Electronic Search Strategies) [22] by another experienced
information specialist. To identify additional relevant
RCTs published outside the time frames of these reviews,
we will compile a list of the unique Medline identification
numbers of all relevant articles, and perform a related arti-
cles search in Medline. Search results will be limited to
the top general medicine journals and related specialty
journals as determined by impact factor. This technique
has been shown to be effective in identifying relevant
studies [23], has been used recently by reviews in several
fields including hypertension, and will increase efficiency
in study identification in the presence of an already large
and established evidence base.
Study selection and data extraction
Review of citations based on title, keywords and abstract
(Level 1 screening) and full text articles (Level 2 screening)
will be carried out independently by two reviewers. Level 1
citations deemed potentially relevant or unclear will be
carried forward to Level 2. Study selection will be
conducted using Distiller Systematic Review Software
(DSR; Ottawa, ON, Canada). Where consensus is notachieved following discussion, a third member of the
research team will be consulted to settle disagree-
ments. The process of literature selection will be
reported using a flow diagram as recommended by the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement [24].
Data extraction and risk of bias assessment
Primary data collection will be performed independently
by two reviewers using a standardized data collection
form implemented using SR Distiller Software (Evidence
Partners Incorporated, Ottawa, Ontario, Canada); this
software will also be used to compare collected data for
accuracy and agreement, with disagreements being
settled by discussion. The following information will be
collected from all eligible studies: authorship list, year
and journal of publication, countries of study, funding
source, group sample sizes, study inclusion criteria, age
distribution, gender distribution, ethnicity distribution,
patient comorbidity history, past/present medication
use and all relevant outcome information. To assess
study risk of bias, all RCTs will be reviewed using the
Cochrane Risk of Bias (RoB) tool [25]. Disagreements
will be resolved through discussion or by third party
adjudication.
Data analysis
Studies of first line therapy (that is, mainly monotherapies
unless otherwise rationalized to consider combination
therapies) and second line therapy (that is, mainly
combination therapies) will be analyzed separately to
maintain clinical homogeneity in terms of patient character-
istics. Among combination therapy regimens, we will also
explore analyses to assess whether there is a differential
clinical benefit between combinations involving a thiazide
diuretic versus those which do not.
Approach to analysis
We will begin with a narrative overview of studies included
in the review which will provide insights regarding the
degree of clinical and methodologic homogeneity among
included RCTs, thereby helping to explore the assumptions
of homogeneity and similarity for network meta-analysis
[26]. Study of statistical heterogeneity as measured by
values of I2 within pairwise meta-analyses will also con-
tribute to this assessment. Where assumptions are judged
reasonable, network meta-analysis (NMA) will be carried
out for each clinical outcome separately; NMA is an
approach to evidence synthesis which allows for the
combination of direct and indirect evidence to compare
three or more treatments in a unified analysis. Indirect
comparisons between treatments A and B based on a
common comparator C where no trials of A versus B
exist (that is, no direct evidence) but trials of A versus C
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ginally proposed by Bucher et al. [27], and Lumley [28]
and Lu and Ades [29] subsequently developed extensions
of this methodology. In addition to estimating all pairwise
comparisons between treatments in a network, this
technique can also be used to estimate probabilities of
treatment of superiority to rank the treatments. As part of
this will involve analyses that include combination therapies,
recent methods proposed by Mills and Thorlund may be
explored [30].
Addressing clinical and methodological heterogeneity
Findings from risk of bias assessments of included studies
will inform sensitivity analyses, including meta-regression
or exclusion of higher risk studies to address the impact
of perceived study deficiencies. Meta-regression and/or
removal of studies from the treatment network to address
clinically important variations between studies with regard
to gender distribution, age distribution, history of chosen
clinically relevant baseline comorbidities and other relevant
factors will be considered. If several trials contain per-
centages of diabetic patients, sensitivity analyses excluding
these studies will be performed.
Clinical practice for patients with hypertension has
evolved over time, including the emergence of common
use of co-interventions such as statins and aspirin. To
explore the potential impact of such changes, we will
explore meta-regression analyses using the network meta-
analysis approach to adjust for year of initiation of patient
enrollment in each study. This may be a helpful proxy
in the absence of other information about background
treatments.
Assessment of coherence
This review will consist of a mixture of both direct evi-
dence (that is, head to head comparisons between different
antihypertensive agents or classes) and indirect evi-
dence (that is, inactively controlled studies of the differ-
ent agents or classes). As described elsewhere [31,32],
there is a need to verify that findings generated from
synthesis of direct and indirect data do not differ more
than one would expect by chance. We will employ
methods described by Dias et al. [33] to assess the validity
of this assumption in this work. As statistics alone cannot
always be replied upon to identify important clinical or
methodologic differences between studies, we will also
employ evidence tables of study characteristics to further
assess homogeneity.
Reporting of findings from analyses
Full graphical and numeric presentations of findings
[34] will be provided to convey the results of our
work. This will include network diagrams showing the
structure of available evidence for all possible treatmentcomparisons, summary point estimates and 95% cred-
ible intervals for all pairwise comparisons, and esti-
mated probabilities that each therapy is deemed ‘best’
for each outcome along with associated average rank-
ings. Forest plots of summary estimates as well as
rankograms [34] will be used to clearly delineate any
important variations from the primary analysis for sub-
group effects.Discussion
The proposed review will add to the literature in several
ways. To our knowledge, the planned review includes
analyses for certain clinical outcomes which have not
been the subject of past network meta-analyses, and
others which are important for consideration of harms
and patients’ quality of life. The review will also pursue
updates of comparisons of therapies using a network
meta-analysis approach for several clinical outcomes
which have not been studied using this technique since
2003, and thus for which considerable new data are likely
available. The review will generate new information by
addressing combination therapies for hypertension, both
(i) in comparison to monotherapies in specific patient
populations where either might be used, and (ii) in
patients who have moderate to severe hypertension. To
our knowledge, neither has been addressed using
network meta-analysis. Finally, we will also improve
upon limitations of past reviews by including improved
assessment and accounting for the effects of clinical
heterogeneity between studies.
There are potential challenges to the planned review.
Clinical expertise and preliminary review of a sample
of relevant trials for this research shows that in some
studies, while patients are randomized to one active
antihypertensive agent to address the study’s research
question, additional anti-hypertensive medications may be
prescribed to patients at the physicians’ discretion. While
these additional treatments may have implications for the
additional effects seen, outcome data for those remaining
strictly on the prescribed treatments may not be available.
This may be a limiting factor concerning the ‘purity’ of
some included trial data. We anticipate at least a moderate
degree of clinical heterogeneity with regard to the
clinical populations enrolled from study to study. If
the extent of included literature turns out to be small,
the ability to explore heterogeneity could be limited;
however, past works suggest considerable evidence
will be found. There are many possible outcomes of
interest to be studied in relation to hypertensive pa-
tients. We have attempted to identify outcomes that
are clinically important and can be studied using network
meta-analysis to produce important information in a
timely fashion.
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Appendix: Medline search strategy
Database: Ovid MEDLINE(R) In-Process and Other
Non-Indexed Citations and Ovid MEDLINE(R) <1946 to
Present> Search Strategy:
1. exp Hypertension/ (199996)
2. hypertens*. tw. (294265)
3. ((high* or rais* or elevat* or heighten* or increas*) adj3
(“blood pressure” or “diastolic pressure” or “systolic
pressure” or “pulse pressure”)). tw. (46697)
4. ((high* or rais* or elevat* or heighten* or increas*)
adj3 (BP or DBP or SBP)). tw. (11512)
5. exp Cardiovascular Diseases/pc [Prevention &
Control] (142328)
6. ((borderline or pre-disease* or pre-clinical* or
preclinical* or sub-clinical* or subclinical* or pre-
morbid* or premorbid* or risk* or susceptib* or
pre-dispos* or predispos* or predict* or probabilit*
or likelihood or likeliness or prevent*) adj3
(cardiovascular or cardiometabolic* or cardio-
metabolic* or coronary disease* or heart disease* or
heart attack* or heart failure or myocardial
infarction* or coronary artery disease* or CVD or
peripheral artery disease* or PAD or CHD or CAD
or arteriosclerosis or atherosclerosis or stroke)). tw.
(130079)
7. or/1-6 (568110)
8. exp hypertension/dt [drug therapy] (54046)
9. exp Sodium Chloride Symporter Inhibitors/ (11688)
10. ((thiazide or benzothiadiazine or benzo-thiadiazine
or potassium depleting) adj1 diuretic$1).tw. (2092)
11. (sodium chloride symporter inhibitor$1 or sodium
chloride cotransporter inhibitor$1 or sodium
chloride co-transporter inhibitor$1 or thiazide
sensitive NaCl cotransporter inhibitor$1 or thiazide
sensitive NaCl co-transporter inhibitor$1). tw. (0)
12. exp Chlorothiazide/ (7612)
13. (chlorothiazide or Alurene or Chlorosal or
Chlotride or Chlorothiazid or Chlorothiazidum or
Chlorthiazid or Chlorthiazide or Chrthiazidum or
Chlortiazid or Chlorurit or Chlotride or
Clorotiazide or Clotride or Diuresal or Diuril or
Diurilix or Diurite or Diutrid or Flumen or Minzil
or Neo-dema or SK-Chlorothiazide or Salisan or
Salunil or Saluretil or Saluric or Thiazide or Urinex
or Warduzide or Yadalan). tw. (4691)
14. 58-94-6.rn. (2058)
15. exp Chlorthalidone/ (1316)
16. (chlorthalidone or Apo-Chlorthalidone or
Chlorphthalidolone or Chlorphthalidone or
Chlortalidone or Chlortalidonum or Chlorthalidon
or Clortalidone or Famolin or Hydro-Long or
Hygroton or Igroton or Isoren or Natriuran orOksodolin or oxodolin or Oradil or Oxodolin or
Phthalamodine or Phthalamudine or Racemic
chlorthalidone or Renon or Saluretin or Thalitone
or Urolin or Zambesil). tw. (1144)
17. 77-36-1.rn. (1316)
18. exp Hydrochlorothiazide/ (5737)
19. (Hydrochlorothiazide or “Aquazide H” or Apo-
Hydro or Carozide or Dichlothiazide or Dihydroch-
lorothiazide or Esidrex or Esidrix or Ezide or
HCTZ or Hydrochlorot or HydroDIURIL or
Hydro-par or HydroSaluric or Hypothiazide or
Microzide or Oretic or Sectrazide). tw. (5452)
20. 58-93-5. rn. (5554)
21. exp Hydroflumethiazide/ (141)
22. (Hydroflumethiazide or Bristab or Bristurin or
Di-ademil or Di-adenil or Dihydroflumethiazide or
Diucardin or Diuredemina or Diurometon or
Elodrin or Elodrine or Enjit or Finuret or Flutizide
or Hydol Hydrenox or Hydroflumethiazide or
Hydroflumethiazidum or Hydroflumethizide or
Idroflumetiazide or Leodrine or NaClex or
Olmagran or Rivosil or Robezon or Rodiuran or
Rontyl or saluron or Sisuril or Spandiuril or
Trifluoromethylhydrothiazide or Vergonil).tw. (128)
23. 135-09-1. rn. (141)
24. exp Indapamide/ (850)
25. (indapamide or Arifon or Bajaten or Cormil or
Damide or Fludex or Indaflex or Indapamide or
Indamol or Ipamix or Lozol or Metindamide or
Natrilix or Noranat or Pressurai or Tandix or
Tertensif or Veroxil). tw. (952)
26. 26807-65-8.rn. (850)
27. exp Methyclothiazide/ (106)
28. (methyclothiazide or Aquatensen or Enduron or
Naturon). tw. (105)
29. 135-07-9. rn. (106)
30. exp Metolazone/ (156)
31. (metolazone or Diulo or Microx or Mykrox or
Oldren or Zaroxolyn or Zytanix). tw. (241)
32. 17560-51-9. rn. (156)
33. exp Polythiazide/ (237)
34. (Polythiazide or Drenusil or Nephril or
Polythiazidum or Renese). tw. (198)
35. 346-18-9. rn. (237)
36. exp Angiotensin-Converting Enzyme Inhibitors/
(38358)
37. ((Angiotensin-Converting Enzyme or Angiotensin
I-Converting Enzyme or ACE or Kininase II) adj
(inhibitor* or antagonist*)). tw. (26527)
38. (ACEI or ACEIs). tw. (2465)
39. exp Captopril/ (9515)
40. (Acediur or Aceplus or Acepress or Acepril or
Alopresin or Asisten or Capoten or Captolane or
Captopril or Captoprilum or Captopryl or Captoril
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Hypertil or Hypopress or Isopresol or “L-Captopril”
or Lopirin or Lopril or Novocaptopril or Tenosbon
or Tensoprel or Zapto). tw. (10387)
41. 62571-86-2.rn. (9515)
42. exp Enalapril/ (6105)
43. (Enalapril or Bonuten or Enalaprila or Enalaprilum
or Gadopril or Kinfil). tw. (5429)
44. 75847-73-3. rn. (5546)
45. exp Lisinopril/ (1766)
46. (Lisinopril or Lisinopril dehydrate or Prinivil or
Renacor or Zestril). tw. (1989)
47. 83915-83-7.rn. (1766)
48. (Benazepril hydrochloride or Benazepril HCl or
Briem or Cibace or Cibacen or Cibacen CHF or
Cibacene or Labopol or Lotensin or Lotrel or
Tensanil or Zinadril). tw. (95)
49. benazepril. rn. (467)
50. exp Fosinopril/ (386)
51. (Fosinopril or Dynacil or Fosenopril or Fosinil or
Fosinorm or Fositens or Fozitec or Hiperlex or
Monopril or Newace or Staril or “Tenso Stop” or
Tensocardil). tw. (462)
52. 98048-97-6. rn. (386)
53. exp Ramipril/ (1740)
54. (Ramipril or Acovil or Altace or Carasel or
Cardace or Delix or Hytren or Lostapres or Naprix
or Pramace or Quark or Ramace or Ramiprilum or
Ramipro or Triatec or Tritace or Vesdil or Zabien).
tw. (2455)
55. 87333-19-5. rn. (1740)
56. (Quinapril hydrochloride or Accupril or Accuprin
or Accupron or Acequin or Acuitel or Acuprel or
Asig or Conan or Continucor or Ectren or
Hemokvin or Korec or Koretic or Lidaltrin or
Quinapril or Quinapril HCl or Quinazil). tw. (805)
57. 82586-55-8. rn. (608)
58. exp Perindopril/ (1389)
59. (Aceon or Covapril or Coversyl or Perindopril or
Pirindopril or Prestarium). tw. (1470)
60. 82834-16-0. rn. (1389)
61. (Trandolapril or Gopten or Mavik or Odrik or
Udrik). tw. (569)
62. 87679-37-6.rn. (483)
63. (Moexiril or Fempress or Moex or Moexipril
hydrochloride or Perdix or Univasc). tw. (70)
64. 103775-10-6. rn. (74)
65. exp Calcium Channel Blockers/ (69679)
66. ((calcium or ca) adj2 (blocker* or blockader* or
blocking or antagonist* or inhibitor*)). tw. (33221)
67. exp Amlodipine/ (2732)
68. (Amlodipine or Amlodipine Besylate or Amlodipine
Maleate or Amlodis or Amlor or Astudal or Coroval
or Istin or Lipinox or Norvasc).tw. (3298)69. 88150-42-9. rn. (2732)
70. (Aranidipine or Sapresta). tw. (14)
71. 86780-90-7. rn. (27)
72. (Azelnidipine or Calblock). tw. (148)
73. 123524-52-7. rn. (125)
74. (Barnidipine or Cyress or HypoCa or Libradin or
Mepirodipine). tw. (78)
75. 104713-75-9. rn. (59)
76. (Benidipine or Benidipinum or Coniel). tw. (254)
77. 105979-17-7. rn. (185)
78. (Cilnidipine or Atelec or Cinalong or Siscard). tw.
(164)
79. 132203-70-4. rn. (132)
80. (Clevidipine or Cleviprex). tw. (89)
81. clevidipine. rn. (68)
82. exp Isradipine/ (1325)
83. (Isradipine or Dynacirc or “DynaCirc CR” or
Isradipinum or Lomir or Prescal). tw. (1079)
84. 75695-93-1. rn. (1325)
85. (Efonidipine or Landel). tw. (176)
86. efonidipine.rn. (109)
87. exp Felodipine/ (1083)
88. (Felodipine or Agon or Felo Biochemie or Felo-
Puren or Felobeta or Felocor or Felodipin or
Felodur or Felogamma or Fensel or Flodil or Modip
or Munobal or Perfudal or Plendil or Renedil). tw.
(1370)
89. 72509-76-3. rn. (1083)
90. (Lacidipine or Lacidipinum or Lacimen or Lacipil
or Motens). tw. (372)
91. 103890-78-4.rn. (286)
92. (Lercanidipine or Lacidipinum or Lercadip or
Lerdip or Zanidip). tw. (184)
93. 103890-78-4. rn. (286)
94. (Manidipine or Calslot or Madipine or
Franidipine). tw. (226)
95. 89226-50-6. rn. (181)
96. exp Nicardipine/ (2364)
97. (Nicardipine or Antagonil or Carden SR or
Cardene or Dagan or Flusemide or Lecibral or
Lincil or Loxen or Lucenfal or Nicardipinum or
Perdipine or Ridene or Vasonase). tw. (3363)
98. 55985-32-5. rn. (2364)
99. exp Nifedipine/ (14811)
100. (Nifedipine or Adalat or Afeditab or Citilat or
Cordipin or Cordipine or Corinfar or Fenihidin or
Fenihidine or Fenigidin or Korinfar or Nifediac or
Nifedical or Nifangin or Oxcord or Procardia or
Procardia XL or Vascard). tw. (17914)
101. 21829-25-4.rn. (14811)
102. (Nilvadipine or Escor or Nivadil or
Nilvadipinum). tw. (272)
103. 75530-68-6. rn. (238)
104. exp Nimodipine/ (2372)
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Kenesil or Modus or Nimodipin or Nimodipinum
or Nimotop or Periplum or Remontal). tw. (3996)
106. 66085-59-4. rn. (2372)
107. exp Nisoldipine/ (734)
108. (Nisoldipine or Baymycard or Nisocor or
Nisoldipinum or Sular or Syscor). tw. (973)
109. 63675-72-9. rn. (734)
110. 110.exp Nitrendipine/ (2061)
111. (Nitrendipine or Balminil or Bayotensin or
Baylotensin or Baypresol or Baypress or Cardif or
Gericin or Jutapress or Nidrel or Niprina or Nitre
AbZ or Nitre-Puren or Nitregamma or Nitren 1A
Pharma or Nitren acis or Nitren Lich or Nitrend
KSK or Nitrendepat or Nitrendi Biochemie or
Nitrendidoc or Nitrendimerck or Nitrepin or
Nitrendipin or Nitrendipino or Nitrensal or
Nitrepress or Nitrendipinum or Tensogradal or
Trendinol or Vastensium). tw. (2755)
112. 39562-70-4. rn. (2061)
113. (Pranidipine or Acalas). tw. (33)
114. 99522-79-9. rn. (36)
115. exp Verapamil/ (16518)
116. (Verapamil or Calan or Cordilox or Dexverapamil
or Dilacoran or Falicard or Finoptin or Iproveratril
or Isoptimo or Isoptin or Isoptine or Izoptin or
Lekoptin or Vasolan or Verapamilum or dl-
Verapamil). tw. (20352)
117. 52-53-9. rn. (15706)
118. exp Diltiazem/ (5862)
119. (Diltiazem or Aldizem or Cardil or Cardizem or
Cardizem LA or Dilacor or Dilacor XR or Dilcontin
or Dilren or Dilta-Hexal or Diltiazem
Hydrochloride or Diltiazem Malate or Diltiazemum
or Dilticard or Dilzem or Endrydil or Incoril AP or
Tiazac). tw. (7899)
120. 42399-41-7. rn. (5862)
121. exp Mibefradil/ (519)
122. (mibefradil or Posicor). tw. (621)
123. 116644-53-2. rn. (519)
124. exp Bepridil/ (701)
125. (Bepridil or Bedapin or Bepadin or Cordium or
Unicordium or Vascor). tw. (698)
126. 64706-54-3. rn. (701)
127. exp Fluspirilene/ (103)
128. (fluspirilene or Fluspi or Fluspirilenum or Imap
or Kivat or Redeptin). tw. (226)
129. 1841-19-6. rn. (103)
130. exp Aldosterone Antagonists/ (7103)
131. (aldosterone adj (antagonist* or inhibit*)). tw.
(1112)
132. exp Spironolactone/ (5381)
133. (spironolactone or Acelat or Aldace or Aldactone
or Alderon or Aldopur or Almatol or Altex orAquareduct or Berlactone or duraspiron or
Diatense or Espironolactona or Euteberol or
Flumach or Frumikal or Jenaspiron or Novo-
Spiroton or Practon or Spiractin or Spiresis or
Spirobeta or Spirogamma or Spirolactone or
Spirolang or Spirono-Isis or Spironone or
Spirospare or Uractone or Urusonin or
Veroshpiron or Verospiron or Verospirone or
Xenalon). tw. (4652)
134. 52-01-7. rn. (5381)
135. (Eplerenone or Inspra). tw. (684)
136. Eplerenone. rn. (541)
137. exp Adrenergic Antagonists/ (111121)
138. ((Adrenergic or alpha-adrenergic or beta-
adrenergic) adj3 (block* or alpha-block* or beta-
block* or antagonist* or alpha-antagonist* or beta-
antagonist*)). tw. (17756)
139. ((alpha1 or “alpha-1” or alpha2 or “alpha-2” or
beta or beta1 or “beta-1” or beta2 or “beta-2” or
beta3 or “beta-3”) adj2 (block* or antagonist*)). tw.
(54717)
140. (adrenolytic* or anti-adrenergic* or
antiadrenergic*). tw. (1347)
141. exp Phenoxybenzamine/ (4990)
142. (Phenoxybenzamine or Bensylyt or Benzylyt or
Dibenylene or Dibenyline or Dibenziran or
Dibenzylin or Dibenzyline or Dibenzyran or
Fenossibenzamina or Fenoxibenzamina or
Phenoxybenzaminum). tw. (3753)
143. 59-96-1. rn. (4990)
144. exp Phentolamine/ (9050)
145. (Phentolamine or Dibasin or Fentolamin or
Phentolaminum or Regitine or Regityn or Rogitine
or “Z-Max”). tw. (9471)
146. 50-60-2. rn. (9050)
147. exp Tolazoline/ (993)
148. (Tolazoline or Artonil or Benzalolin or
Benzazoline or Benzidazol or Benzolin or
Benzylimidazoline or Dilatol ASI or Divascol or
Imidalin or Kasimid or Lambril or Olitensol or
Peripherine or Phenylmethylimidazoline or Prefaxil
or Pridazole or Priscol or Priscoline or Tolazolin or
Tolazolinum or Vasimid or Vasodil or Vasodilatan).
tw. (874)
149. 59-98-3. rn. (993)
150. (Alfuzosin or Alfetim or Afusozine or
Alphuzosine or Alfuzosinum or Benestan or Urion
or UroXatral or Xatral). tw. (383)
151. 81403-80-7. rn. (307)
152. exp Prazosin/ (8129)
153. (Prazosin or Furazosin or Minipress or Pratsiol or
Prazosinum). tw. (9945)
154. 19216-56-9. rn. (7348)
155. exp Doxazosin/ (1097)
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Cardular or Cardura or Carduran or Carduran Neo
or Diblocin or Doxa-Puren or Doxacor or
Doxagamma or Doxamax or Doxatensa or
DoxaUro or Doxazomerck or Doxazosine or
Doxazosinum or Gen-Doxazosin or Jutalar or
MTW-Doxazosin or Novo-Doxazosin or Progandol
Neo or Uriduct or Zoxan). tw. (1257)
157. 74191-85-8. rn. (1097)
158. (Tamsulosin or Flomax or Tamsulosine or
Tamsulosinum). tw. (973)
159. 106133-20-4. rn. (769)
160. (Terazosin or Adecur or Apo-Terazosin or Blavin
or Deflox or Dysalfa or Flotrin or Flumarc or
Fosfomic or Heitrin or Hytrin or Hytrine or
Magnurol or Novo-Terazosin or Nu-Terazosin or
Sutif or Tazusin or Terazoflo or Vasomet or
Zayasel). tw. (691)
161. 63590-64-7. rn. (529)
162. (Atipamezole or Antisedan or Atipamezol or
Atipamezolum). tw. (597)
163. 104054-27-5. rn. (405)
164. exp Idazoxan/ (1388)
165. (Idazoxan or Idazoxanum). tw. (1828)
166. 79944-58-4. rn. (1388)
167. exp Yohimbine/ (19692)
168. (Yohimbine or Aphrosol or Aphrodine or
Aphrodyne or Corynine or Corynanthine or
Pluriviron or Quebrachin or Quebrachine or
Rauhimbine or Rauwolscine or Yocon or Yohimbin
or Yohimex). tw. (7878)
169. 146-48-5. rn. (5437)
170. (Carvedilol or Carvedilolum or Coreg or
Coropres or Dilatrend or Eucardic or Kredex or
Querto). tw. (2195)
171. 72956-09-3. rn. (1965)
172. exp Labetalol/ (1667)
173. (Labetalol or Albetol or Apo-Labetalol or
Dilevalol or Dilevalolum or Labetolol or
Normodyne or Presolol or Trandate). tw. (1897)
174. 36894-69-6. rn. (1667)
175. exp Alprenolol/ (2174)
176. (Alprenolol or Alfeprol or Alpheprol or
Alprenololum or Aptin or Aptin-Duriles or Aptina
or Aptine) .tw. (983)
177. 13655-52-2. rn. (1067)
178. (Bucindolol or Bucindololum). tw. (138)
179. Bucindolol. rn. (110)
180. exp Carteolol/ (336)
181. (Carteolol or Carteololum). tw. (425)
182. 51781-06-7. rn. (336)
183. exp Nadolol/ (750)
184. (Nadolol or Anabet or Corgard or Corzide or
Nadololum or Solgol). tw. (1031)185. 42200-33-9. rn. (750)
186. exp Oxprenolol/ (1011)
187. (Oxprenolol or Coretal or Koretal or
Oxprenololum or Slow Trasicor or Tevacor or
Trasicor). tw. (1036)
188. 6452-71-7. rn. (1011)
189. exp Penbutolol/ (174)
190. (Penbutolol or Betapressin). tw. (236)
191. 36507-48-9. rn. (174)
192. exp Pindolol/ (3689)
193. (Pindolol or Betapindol or “Blocklin L” or
Calvisken or Carvisken or Decreten or Durapindol
or Glauco-Viskin or Pectobloc or Pinbetol or
Pindololum or Prinodolol or Pyn astin or Visken).
tw. (2706)
194. 13523-86-9. rn. (3614)
195. exp Propranolol/ (30773)
196. (Propranolol or Anaprilin or Anapriline or
Avlocardyl or Betadren or Betalong or beta-
Propranolol or Corpendol or Dexpropranolol or
Dociton or Euprovasin or Inderal or Obsidan or
Obzidan or Propanix or Propranololum or Reducor
or Sawatal or Sumial or Rexigen). tw. (30160)
197. 525-66-6. rn. (30773)
198. exp Sotalol/ (1903)
199. (Sotalol or Darob or Sotalolum or beta-Cardone).
tw. (2376)
200. 3930-20-9. rn. (1903)
201. exp Timolol/ (3166)
202. (Timolol or Blocadren or Timacar). tw. (3532)
203. 26839-75-8. rn. (3166)
204. Eucommia bark$1. tw. (7)
205. exp Atenolol/ (4674)
206. (Atenolol or Tenormin or Tenormine). tw. (6104)
207. 29122-68-7. rn. (4674)
208. exp Betaxolol/ (624)
209. (Betaxolol or Betaxololum). tw. (783)
210. 63659-18-7. rn. (624)
211. exp Bisoprolol/ (771)
212. (Bisoprolol or Concor). tw. (956)
213. 66722-44-9. rn. (771)
214. exp Celiprolol/ (380)
215. (Celiprolol or Celiprololum or Selectol). tw. (467)
216. 56980-93-9. rn. (380)
217. Esmolol. tw. (935)
218. Esmolol. rn. (768)
219. exp Metoprolol/ (4611)
220. (Metoprolol or Beatrolol or Beloc-Duriles or
Betaloc or Betalok or Corvitol or Lopressor or
Meijoprolol or Metohexal or Metoprololum or
Metrol or Minax or Neobloc or Preblok or Presolol
or Selokeen or Seloken or Spesicor or Spesikor or
Toprol). tw. (5533)
221. 37350-58-6. rn. (4611)
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Nobiten or Silostar or Vasoxen). tw. (603)
223. Nebivolol. rn. (534)
224. exp Angiotensin Receptor Antagonists/ (15906)
225. (angiotensin adj3 (antagonist* or block*)). tw.
(13473)
226. (Sartan or Sartans). tw. (154)
227. ARBS. tw. (1784)
228. exp Losartan/ (5446)
229. (Losartan or Cozaar or Losartan Monopotassium
Salt or Losartan Potassium). tw. (6460)
230. 114798-26-4. rn. (5446)
231. Candesartan. tw. (1988)
232. 139481-59-7. rn. (1526)
233. (Valsartan or Diovan or Kalpress or Miten or
Nisis or Provas or Tareg or Vals or Valtan or
Valzaar). tw. (1957)
234. 137862-53-4. rn. (1522)
235. (Irbesartan or Aprovel or Avapro or Karvea). tw.
(1154)
236. 138402-11-6. rn. (948)
237. (Telmisartan or Kinzalmono or Micardis or
Pritor). tw. (1220)
238. 144701-48-4. rn. (1023)
239. (Eprosartan or Teveten). tw. (272)
240. 133040-01-4. rn. (244)
241. (Benicar or Olmesartan or Omesartan or
Olmetec or Votum). tw. (796)
242. 144689-24-7. rn. (293)
243. Azilsartan. tw. (28)
244. Azilsartan. rn. (17)
245. exp Hydralazine/ (4220)
246. (Hydralazine or Apresoline or Apressin or
Apressoline or Aprezolin or Hydrallazin or
Hydrazinophthalazine or Nepresol). tw. (3916)
247. 86-54-4. rn. (4005)
248. (Dihydralazine or Depressan or Dihydrallazine or
Dihydrazinophthalazin or Hypopresol or Nepresol
or Nepresolin or Nepressol or Ophthazin or
Tonolysin). tw. (470)
249. 484-23-1. rn. (387)
250. exp Minoxidil/ (1306)
251. (Minoxidil or Alopexil or Alostil or Loniten or
Lonolox or Mintop or Normoxidil or Prexidil or
Regaine or Rogaine or Theroxidil or Tricoxidil). tw.
(1378)
252. 38304-91-5. rn. (1306)
253. (Aliskiren or Tekturna or Enviage or Rasilez or
Riprazo or Sprimeo). tw. (622)
254. Aliskiren. rn. (526)
255. exp Renin/ai [antagonists & inhibitors] (1585)
256. Clonidine/ (12516)
257. (Clonidine or Adesipress or Catapres$3 or
(Catapres adj TTS*) or Chlophazolin or Clofelin orClofenil or Clopheline or Dixarit or Duraclon or
Gemiton or Hemiton or Isoglaucon or Klofelin or
Klofenil or “Nexiclon XR”). tw. (13508)
258. exp Antihypertensive Agents/ (220309)
259. (antihypertensive* or anti-hypertensive*). tw.
(37546)
260. (minizide or polypress). tw. (6)
261. (Polythiazide adj3 Prazosin). tw. (13)
262. 84057-89-6. rn. (2)
263. (Enduronyl or Enduron-deserpidine). tw. (1)
264. (Deserpidine adj3 methyclothiazide). tw. (7)
265. 8057-21-4. rn. (0)
266. “Diutensen-R”. tw. (0)
267. (Reserpine adj3 methyclothiazide). tw. (2)
268. or/8-267 (400861)
269. 7 and 268 (112506)
270. limit 269 to systematic reviews (2552)
271. meta analysis.pt. (37688)
272. exp meta-analysis as topic/ (12567)
273. (meta-analy* or metanaly* or metaanaly* or met
analy* or integrative research or integrative review*
or integrative overview* or research integration or
research overview* or collaborative review*). tw.
(49866)
274. (systematic review* or systematic overview* or
evidence-based review* or evidence-based
overview* or (evidence adj3 (review* or overview*))
or meta-review* or meta-overview* or “review of
reviews” or technology assessment* or HTA or
HTAs). tw. (64768)
275. exp Technology assessment, biomedical/ (8940)
276. health technology assessment winchester england.
jn. (1031)
277. (evidence report technology assessment or
evidence report technology assessment summary).j
n. (204)
278. “cochrane database of systematic reviews”.jn.
(9287)
279. or/271-278 (127337)
280. 269 and 279 (2137)
281. 270 or 280 (3526)
282. limit 281 to human (3414)
283. (in process or publisher or pubmed-not-medline
or in-data-review).st. (1409788)
284. 281 and 283 (85)
285. 282 or 284 (3499)
286. (comment or editorial or interview or letter or
news). pt. (1384444)
287. 285 not 286 (3359)
Appendix: Cochrane Database search strategy
Database: EBM Reviews - Cochrane Database of Sys-
tematic Reviews <2005 to October 2012> Search
Strategy:
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2. hypertens*.ti,ab,kw. (220)
3. ((high* or rais* or elevat* or heighten* or increas*)
adj3 (“blood pressure” or “diastolic pressure” or
“systolic pressure” or “pulse pressure”)).ti,ab,kw.
(53)
4. ((high* or rais* or elevat* or heighten* or increas*)
adj3 (BP or DBP or SBP)).ti,ab,kw. (10)
5. Cardiovascular Diseases pc.kw. (6)
6. ((borderline or pre-disease* or pre-clinical* or
preclinical* or sub-clinical* or subclinical* or pre-
morbid* or premorbid* or risk* or susceptib* or
pre-dispos* or predispos* or predict* or probabilit*
or likelihood or likeliness or prevent*) adj3
(cardiovascular or cardiometabolic* or cardio-
metabolic* or coronary disease* or heart disease* or
heart attack* or heart failure or myocardial
infarction* or coronary artery disease* or CVD or
peripheral artery disease* or PAD or CHD or CAD
or arteriosclerosis or atherosclerosis or stroke)).ti,
ab,kw. (267)
7. or/1-6 (470)
8. hypertension dt.kw. (17)
9. Sodium Chloride Symporter Inhibitors.kw. (3)
10. ((thiazide or benzothiadiazine or benzo-thiadiazine
or potassium depleting) adj1 diuretic$1).ti,ab,kw.
(10)
11. (sodium chloride symporter inhibitor$1 or sodium
chloride cotransporter inhibitor$1 or sodium
chloride co-transporter inhibitor$1 or thiazide
sensitive NaCl cotransporter inhibitor$1 or thiazide
sensitive NaCl co-transporter inhibitor$1).ti,ab,kw.
(3)
12. Chlorothiazide.kw. (1)
13. (chlorothiazide or Alurene or Chlorosal or
Chlotride or Chlorothiazid or Chlorothiazidum or
Chlorthiazid or Chlorthiazide or Chlorthiazidum or
Chlortiazid or Chlorurit or Chlotride or
Clorotiazide or Clotride or Diuresal or Diuril or
Diurilix or Diurite or Diutrid or Flumen or Minzil
or Neo-dema or SK-Chlorothiazide or Salisan or
Salunil or Saluretil or Saluric or Thiazide or Urinex
or Warduzide or Yadalan).ti,ab,kw. (14)
14. Chlorthalidone.kw. (0)
15. (chlorthalidone or Apo-Chlorthalidone or
Chlorphthalidolone or Chlorphthalidone or
Chlortalidone or Chlortalidonum or Chlorthalidon
or Clortalidone or Famolin or Hydro-Long or
Hygroton or Igroton or Isoren or Natriuran or
Oksodolin or oxodolin or Oradil or Oxodolin or
Phthalamodine or Phthalamudine or Racemic
chlorthalidone or Renon or Saluretin or Thalitone
or Urolin or Zambesil).ti,ab,kw. (0)
16. Hydrochlorothiazide.kw. (0)17. (Hydrochlorothiazide or “Aquazide H” or Apo-
Hydro or Carozide or Dichlothiazide or
Dihydrochlorothiazide or Esidrex or Esidrix or
Ezide or HCTZ or Hydrochlorot or HydroDIURIL
or Hydro-par or HydroSaluric or Hypothiazide or
Microzide or Oretic or Sectrazide).ti,ab,kw. (1)
18. Hydroflumethiazide.kw. (0)
19. (Hydroflumethiazide or Bristab or Bristurin or Di-
ademil or Di-adenil or Dihydroflumethiazide or
Diucardin or Diuredemina or Diurometon or
Elodrin or Elodrine or Enjit or Finuret or Flutizide
or Hydol Hydrenox or Hydroflumethiazide or
Hydroflumethiazidum or Hydroflumethizide or
Idroflumetiazide or Leodrine or NaClex or
Olmagran or Rivosil or Robezon or Rodiuran or




21. (indapamide or Arifon or Bajaten or Cormil or
Damide or Fludex or Indaflex or Indapamide or
Indamol or Ipamix or Lozol or Metindamide or
Natrilix or Noranat or Pressurai or Tandix or
Tertensif or Veroxil).ti,ab,kw. (0)
22. Methyclothiazide.kw. (0)
23. (methyclothiazide or Aquatensen or Enduron or
Naturon).ti,ab,kw. (0)
24. Metolazone.kw. (0)
25. (metolazone or Diulo or Microx or Mykrox or
Oldren or Zaroxolyn or Zytanix).ti,ab,kw. (0)
26. Polythiazide.kw. (0)
27. (Polythiazide or Drenusil or Nephril or
Polythiazidum or Renese).ti,ab,kw. (0)
28. Angiotensin-Converting Enzyme Inhibitors.kw. (12)
29. ((Angiotensin-Converting Enzyme or Angiotensin
I-Converting Enzyme or ACE or Kininase II) adj
(inhibitor* or antagonist*)).ti,ab,kw. (45)
30. (ACEI or ACEIs).ti,ab,kw. (18)
31. Captopril.kw. (0)
32. (Acediur or Aceplus or Acepress or Acepril or
Alopresin or Asisten or Capoten or Captolane or
Captopril or Captoprilum or Captopryl or Captoril
or Cesplon or Dilabar or Farcopril or Garranil or
Hypertil or Hypopress or Isopresol or “L-Captopril”
or Lopirin or Lopril or Novocaptopril or Tenosbon
or Tensoprel or Zapto).ti,ab,kw. (2)
33. Enalapril.kw. (1)
34. (Enalapril or Bonuten or Enalaprila or Enalaprilum
or Gadopril or Kinfil).ti,ab,kw. (2)
35. Lisinopril.kw. (0)
36. (Lisinopril or Lisinopril dehydrate or Prinivil or
Renacor or Zestril).ti,ab,kw. (1)
37. (Benazepril hydrochloride or Benazepril HCl or
Briem or Cibace or Cibacen or Cibacen CHF or
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Tensanil or Zinadril).ti,ab,kw. (0)
38. Fosinopril.kw. (1)
39. (Fosinopril or Dynacil or Fosenopril or Fosinil or
Fosinorm or Fositens or Fozitec or Hiperlex or
Monopril or Newace or Staril or “Tenso Stop” or
Tensocardil).ti,ab,kw. (1)
40. Ramipril.kw. (0)
41. (Ramipril or Acovil or Altace or Carasel or
Cardace or Delix or Hytren or Lostapres or Naprix
or Pramace or Quark or Ramace or Ramiprilum or
Ramipro or Triatec or Tritace or Vesdil or Zabien).
ti,ab,kw. (2)
42. (Quinapril hydrochloride or Accupril or Accuprin
or Accupron or Acequin or Acuitel or Acuprel or
Asig or Conan or Continucor or Ectren or
Hemokvin or Korec or Koretic or Lidaltrin or
Quinapril or Quinapril HCl or Quinazil).ti,ab,kw.
(0)
43. Perindopril.kw. (1)
44. (Aceon or Covapril or Coversyl or Perindopril or
Pirindopril or Prestarium).ti,ab,kw. (1)
45. (Trandolapril or Gopten or Mavik or Odrik or
Udrik).ti,ab,kw. (0)
46. (Moexiril or Fempress or Moex or Moexipril
hydrochloride or Perdix or Univasc).ti,ab,kw. (0)
47. Calcium Channel Blockers.kw. (35)
48. ((calcium or ca) adj2 (blocker* or blockader* or
blocking or antagonist* or inhibitor*)).ti,ab,kw. (60)
49. Amlodipine.kw. (0)
50. (Amlodipine or Amlodipine Besylate or
Amlodipine Maleate or Amlodis or Amlor or
Astudal or Coroval or Istin or Lipinox or Norvasc).
ti,ab,kw. (2)
51. (Aranidipine or Sapresta).ti,ab,kw. (0)
52. (Azelnidipine or Calblock).ti,ab,kw. (0)
53. (Barnidipine or Cyress or HypoCa or Libradin or
Mepirodipine).ti,ab,kw. (0)
54. (Benidipine or Benidipinum or Coniel).ti,ab,kw. (0)
55. (Cilnidipine or Atelec or Cinalong or Siscard).ti,ab,
kw. (0)
56. (Clevidipine or Cleviprex).ti,ab,kw. (0)
57. Isradipine.kw. (0)
58. (Isradipine or Dynacirc or “DynaCirc CR” or
Isradipinum or Lomir or Prescal).ti,ab,kw. (1)
59. (Efonidipine or Landel).ti,ab,kw. (0)
60. Felodipine.kw. (0)
61. (Felodipine or Agon or Felo Biochemie or Felo-
Puren or Felobeta or Felocor or Felodipin or
Felodur or Felogamma or Fensel or Flodil or Modip
or Munobal or Perfudal or Plendil or Renedil).ti,ab,
kw. (0)
62. (Lacidipine or Lacidipinum or Lacimen or Lacipil
or Motens).ti,ab,kw. (0)63. (Lercanidipine or Lacidipinum or Lercadip or
Lerdip or Zanidip).ti,ab,kw. (0)
64. (Manidipine or Calslot or Madipine or
Franidipine).ti,ab,kw. (0)
65. Nicardipine.kw. (0)
66. (Nicardipine or Antagonil or Carden SR or
Cardene or Dagan or Flusemide or Lecibral or
Lincil or Loxen or Lucenfal or Nicardipinum or
Perdipine or Ridene or Vasonase).ti,ab,kw. (1)
67. Nifedipine.kw. (5)
68. (Nifedipine or Adalat or Afeditab or Citilat or
Cordipin or Cordipine or Corinfar or Fenihidin or
Fenihidine or Fenigidin or Korinfar or Nifediac or
Nifedical or Nifangin or Oxcord or Procardia or
Procardia XL or Vascard).ti,ab,kw. (10)
69. (Nilvadipine or Escor or Nivadil or Nilvadipinum).
ti,ab,kw. (0)
70. Nimodipine.kw. (5)
71. (Nimodipine or Admon or Brainal or Calnit or
Kenesil or Modus or Nimodipin or Nimodipinum
or Nimotop or Periplum or Remontal).ti,ab,kw. (10)
72. Nisoldipine.kw. (0)
73. (Nisoldipine or Baymycard or Nisocor or
Nisoldipinum or Sular or Syscor).ti,ab,kw. (0)
74. Nitrendipine.kw. (0)
75. (Nitrendipine or Balminil or Bayotensin or
Baylotensin or Baypresol or Baypress or Cardif or
Gericin or Jutapress or Nidrel or Niprina or Nitre
AbZ or Nitre-Puren or Nitregamma or Nitren 1A
Pharma or Nitren acis or Nitren Lich or Nitrend
KSK or Nitrendepat or Nitrendi Biochemie or
Nitrendidoc or Nitrendimerck or Nitrepin or
Nitrendipin or Nitrendipino or Nitrensal or
Nitrepress or Nitrendipinum or Tensogradal or
Trendinol or Vastensium).ti,ab,kw. (0)
76. (Pranidipine or Acalas).ti,ab,kw. (0)
77. Verapamil.kw. (3)
78. (Verapamil or Calan or Cordilox or Dexverapamil
or Dilacoran or Falicard or Finoptin or Iproveratril
or Isoptimo or Isoptin or Isoptine or Izoptin or
Lekoptin or Vasolan or Verapamilum or dl-
Verapamil).ti,ab,kw. (6)
79. Diltiazem.kw. (1)
80. (Diltiazem or Aldizem or Cardil or Cardizem or
Cardizem LA or Dilacor or Dilacor XR or Dilcontin
or Dilren or Dilta-Hexal or Diltiazem
Hydrochloride or Diltiazem Malate or Diltiazemum
or Dilticard or Dilzem or Endrydil or Incoril AP or
Tiazac).ti,ab,kw. (3)
81. Mibefradil.kw. (0)
82. (mibefradil or Posicor).ti,ab,kw. (1)
83. Bepridil.kw. (0)
84. (Bepridil or Bedapin or Bepadin or Cordium or
Unicordium or Vascor).ti,ab,kw. (0)
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86. (fluspirilene or Fluspi or Fluspirilenum or Imap or
Kivat or Redeptin).ti,ab,kw. (1)
87. Aldosterone Antagonists.kw. (3)
88. (aldosterone adj (antagonist* or inhibit*)).ti,ab,kw.
(6)
89. Spironolactone.kw. (2)
90. (spironolactone or Acelat or Aldace or Aldactone
or Alderon or Aldopur or Almatol or Altex or
Aquareduct or Berlactone or duraspiron or
Diatense or Espironolactona or Euteberol or
Flumach or Frumikal or Jenaspiron or Novo-
Spiroton or Practon or Spiractin or Spiresis or
Spirobeta or Spirogamma or Spirolactone or
Spirolang or Spirono-Isis or Spironone or
Spirospare or Uractone or Urusonin or
Veroshpiron or Verospiron or Verospirone or
Xenalon).ti,ab,kw. (3)
91. (Eplerenone or Inspra).ti,ab,kw. (1)
92. Adrenergic Antagonists.kw. (1)
93. ((Adrenergic or alpha-adrenergic or beta-
adrenergic) adj3 (block* or alpha-block* or beta-
block* or antagonist* or alpha-antagonist* or beta-
antagonist*)).ti,ab,kw. (47)
94. ((alpha1 or “alpha-1” or alpha2 or “alpha-2” or beta
or beta1 or “beta-1” or beta2 or “beta-2” or beta3 or
“beta-3”) adj2 (block* or antagonist*)).ti,ab,kw. (69)
95. (adrenolytic* or anti-adrenergic* or
antiadrenergic*).ti,ab,kw. (0)
96. Phenoxybenzamine.kw. (0)
97. (Phenoxybenzamine or Bensylyt or Benzylyt or
Dibenylene or Dibenyline or Dibenziran or
Dibenzylin or Dibenzyline or Dibenzyran or
Fenossibenzamina or Fenoxibenzamina or
Phenoxybenzaminum).ti,ab,kw. (0)
98. Phentolamine.kw. (0)
99. (Phentolamine or Dibasin or Fentolamin or
Phentolaminum or Regitine or Regityn or Rogitine
or “Z-Max”).ti,ab,kw. (0)
100. Tolazoline.kw. (0)
101. (Tolazoline or Artonil or Benzalolin or Benzazoline
or Benzidazol or Benzolin or Benzylimidazoline or
Dilatol ASI or Divascol or Imidalin or Kasimid or
Lambril or Olitensol or Peripherine or
Phenylmethylimidazoline or Prefaxil or Pridazole or
Priscol or Priscoline or Tolazolin or Tolazolinum or
Vasimid or Vasodil or Vasodilatan).ti,ab,kw. (0)
102. (Alfuzosin or Alfetim or Afusozine or
Alphuzosine or Alfuzosinum or Benestan or Urion
or UroXatral or Xatral).ti,ab,kw. (2)
103. Prazosin.kw. (2)
104. (Prazosin or Furazosin or Minipress or Pratsiol or
Prazosinum).ti,ab,kw. (2)
105. Doxazosin.kw. (2)106. (Doxazosin or Alfamedin or Apo-Doxazosin or
Cardular or Cardura or Carduran or Carduran
Neo or Diblocin or Doxa-Puren or Doxacor or
Doxagamma or Doxamax or Doxatensa or
DoxaUro or Doxazomerck or Doxazosine or
Doxazosinum or Gen-Doxazosin or Jutalar or
MTW-Doxazosin or Novo-Doxazosin or
Progandol Neo or Uriduct or Zoxan).ti,ab,kw.
(3)
107. (Tamsulosin or Flomax or Tamsulosine or
Tamsulosinum).ti,ab,kw. (5)
108. (Terazosin or Adecur or Apo-Terazosin or Blavin
or Deflox or Dysalfa or Flotrin or Flumarc or
Fosfomic or Heitrin or Hytrin or Hytrine or
Magnurol or Novo-Terazosin or Nu-Terazosin or
Sutif or Tazusin or Terazoflo or Vasomet or
Zayasel).ti,ab,kw. (3)
109. (Atipamezole or Antisedan or Atipamezol or
Atipamezolum).ti,ab,kw. (0)
110. Idazoxan.kw. (0)
111. (Idazoxan or Idazoxanum).ti,ab,kw. (0)
112. Yohimbine.kw. (1)
113. (Yohimbine or Aphrosol or Aphrodine or
Aphrodyne or Corynine or Corynanthine or
Pluriviron or Quebrachin or Quebrachine or
Rauhimbine or Rauwolscine or Yocon or Yohimbin
or Yohimex).ti,ab,kw. (2)
114. (Carvedilol or Carvedilolum or Coreg or
Coropres or Dilatrend or Eucardic or Kredex or
Querto).ti,ab,kw. (1)
115. Labetalol.kw. (0)
116. (Labetalol or Albetol or Apo-Labetalol or
Dilevalol or Dilevalolum or Labetolol or
Normodyne or Presolol or Trandate).ti,ab,kw. (1)
117. Alprenolol.kw. (0)
118. (Alprenolol or Alfeprol or Alpheprol or
Alprenololum or Aptin or Aptin-Duriles or Aptina
or Aptine).ti,ab,kw. (0)
119. (Bucindolol or Bucindololum).ti,ab,kw. (0)
120. Carteolol.kw. (0)
121. (Carteolol or Carteololum).ti,ab,kw. (0)
122. Nadolol.kw. (0)
123. (Nadolol or Anabet or Corgard or Corzide or
Nadololum or Solgol).ti,ab,kw. (0)
124. Oxprenolol.kw. (0)
125. (Oxprenolol or Coretal or Koretal or
Oxprenololum or Slow Trasicor or Tevacor or
Trasicor).ti,ab,kw. (1)
126. Penbutolol.kw. (0)
127. (Penbutolol or Betapressin).ti,ab,kw. (0)
128. Pindolol.kw. (2)
129. (Pindolol or Betapindol or “Blocklin L” or
Calvisken or Carvisken or Decreten or Durapindol
or Glauco-Viskin or Pectobloc or Pinbetol or
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ab,kw. (2)
130. Propranolol. kw. (5)
131. (Propranolol or Anaprilin or Anapriline or
Avlocardyl or Betadren or Betalong or beta-
Propranolol or Corpendol or Dexpropranolol or
Dociton or Euprovasin or Inderal or Obsidan or
Obzidan or Propanix or Propranololum or Reducor
or Sawatal or Sumial or Rexigen).ti,ab,kw. (9)
132. Sotalol.kw. (0)
133. (Sotalol or Darob or Sotalolum or beta-Cardone).
ti,ab,kw. (2)
134. Timolol.kw. (1)
135. (Timolol or Blocadren or Timacar).ti,ab,kw. (3)
136. Eucommia bark$1.ti,ab,kw. (0)
137. Atenolol.kw. (1)
138. (Atenolol or Tenormin or Tenormine).ti,ab,kw.
(2)
139. Betaxolol.kw. (0)
140. (Betaxolol or Betaxololum).ti,ab,kw. (0)
141. Bisoprolol.kw. (0)
142. (Bisoprolol or Concor).ti,ab,kw. (0)
143. Celiprolol.kw. (1)




147. (Metoprolol or Beatrolol or Beloc-Duriles or
Betaloc or Betalok or Corvitol or Lopressor or
Meijoprolol or Metohexal or Metoprololum or
Metrol or Minax or Neobloc or Preblok or Presolol
or Selokeen or Seloken or Spesicor or Spesikor or
Toprol).ti,ab,kw. (2)
148. (Nebivolol or Bystolic or Lobivon or Nebilet or
Nobiten or Silostar or Vasoxen).ti,ab,kw. (0)
149. Angiotensin Receptor Antagonists.kw. (7)
150. (angiotensin adj3 (antagonist* or block*)).ti,ab,kw.
(18)
151. (Sartan or Sartans).ti,ab,kw. (0)
152. ARBS.ti,ab,kw. (9)
153. Losartan.kw. (1)
154. (Losartan or Cozaar or Losartan Monopotassium
Salt or Losartan Potassium).ti,ab,kw. (1)
155. Candesartan.ti,ab,kw. (0)
156. (Valsartan or Diovan or Kalpress or Miten or
Nisis or Provas or Tareg or Vals or Valtan or
Valzaar).ti,ab,kw. (0)
157. (Irbesartan or Aprovel or Avapro or Karvea).ti,ab,
kw. (0)
158. (Telmisartan or Kinzalmono or Micardis or
Pritor).ti,ab,kw. (0)
159. (Eprosartan or Teveten).ti,ab,kw. (0)
160. 160 (Benicar or Olmesartan or Omesartan or
Olmetec or Votum).ti,ab,kw. (0)161. Azilsartan.ti,ab,kw. (0)
162. Hydralazine.kw. (1)
163. (Hydralazine or Apresoline or Apressin or
Apressoline or Aprezolin or Hydrallazin or
Hydrazinophthalazine or Nepresol).ti,ab,kw. (5)
164. (Dihydralazine or Depressan or Dihydrallazine or
Dihydrazinophthalazin or Hypopresol or Nepresol
or Nepresolin or Nepressol or Ophthazin or
Tonolysin).ti,ab,kw. (0)
165. Minoxidil.kw. (3)
166. (Minoxidil or Alopexil or Alostil or Loniten or
Lonolox or Mintop or Normoxidil or Prexidil or
Regaine or Rogaine or Theroxidil or Tricoxidil).ti,
ab,kw. (3)
167. (Aliskiren or Tekturna or Enviage or Rasilez or
Riprazo or Sprimeo).ti,ab,kw. (1)
168. Renin ai.kw. (0)
169. Clonidine.kw. (8)
170. (Clonidine or Adesipress or Catapres$3 or
(Catapres adj TTS*) or Chlophazolin or Clofelin or
Clofenil or Clopheline or Dixarit or Duraclon or
Gemiton or Hemiton or Isoglaucon or Klofelin or
Klofenil or “Nexiclon XR”).ti,ab,kw. (18)
171. Antihypertensive Agents.kw. (46)
172. (antihypertensive* or anti-hypertensive*).ti,ab,kw.
(77)
173. (minizide or polypress).ti,ab,kw. (0)
174. (Polythiazide adj3 Prazosin).ti,ab,kw. (0)
175. (Enduronyl or Enduron-deserpidine).ti,ab,kw. (0)
176. (Deserpidine adj3 methyclothiazide).ti,ab,kw. (0)
177. “Diutensen-R”.ti,ab,kw. (0)
178. (Reserpine adj3 methyclothiazide).ti,ab,kw. (0)
179. or/8-178 (240)
180. 7 and 179 (108)
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